Yifan Pharmaceutical Co., Ltd. (SHE:002019)

Yifan Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	785.91	889.39	698.37	1,144	1,336	1,324
Trading Asset Securities	-	-	75.01	95.5	-	46.73
Cash & Short-Term Investments	785.91	889.39	773.38	1,239	1,336	1,371
Cash Growth	-9.41%	15.00%	-37.59%	-7.25%	-2.51%	-12.30%
Accounts Receivable	1,613	1,507	1,209	1,258	1,145	1,102
Other Receivables	124.76	105.57	80.69	112.08	120.16	130.17
Receivables	1,738	1,612	1,290	1,370	1,265	1,232
Inventory	1,202	1,056	928.61	830.97	663.87	583.85
Other Current Assets	241.97	220.86	259.62	249.71	320.22	319.35
Total Current Assets	3,968	3,778	3,251	3,690	3,585	3,506
Property, Plant & Equipment	2,450	2,144	1,752	1,601	1,643	1,491
Long-Term Investments	709.26	691.26	717.04	696.68	640.12	666.23
Goodwill	2,737	2,737	2,737	2,738	2,738	2,750
Other Intangible Assets	1,758	1,826	1,683	751.37	658.21	715.63
Long-Term Accounts Receivable	-	17.74	1.43	2.16	-	-
Long-Term Deferred Tax Assets	230.42	245.21	257.81	291.47	244.38	226.34
Long-Term Deferred Charges	739.94	773.65	964.14	2,592	2,474	2,187
Other Long-Term Assets	81.62	72.29	136.08	181.38	182.71	95.33
Total Assets	12,674	12,286	11,500	12,544	12,165	11,637
Accounts Payable	714.78	609.12	431.36	288.4	350.86	381.19
Accrued Expenses	401.55	393.79	387.69	360.56	219.84	180.43
Short-Term Debt	1,115	1,058	609.05	673.96	1,020	1,193
Current Portion of Long-Term Debt	374.4	544.67	489.77	554.03	419.27	17.67
Current Portion of Leases	14.8	14.22	17.6	17.95	14.54	0.49
Current Income Taxes Payable	44.79	29.21	19.14	29.54	24.19	33.8
Current Unearned Revenue	113.01	113.63	133.23	203.26	94.82	62.68
Other Current Liabilities	254.35	224.76	99.53	71.69	158.53	259.6
Total Current Liabilities	3,033	2,987	2,187	2,199	2,302	2,129
Long-Term Debt	747.17	627.16	812.04	850.17	730.51	447.63
Long-Term Leases	44.2	50.56	66.73	80.69	89.8	0.95
Long-Term Unearned Revenue	122.81	121.21	102.16	107.29	104.12	88.36
Long-Term Deferred Tax Liabilities	44.32	46.51	54.52	140.9	148.28	225.13
Other Long-Term Liabilities	-	26.49	21.86	18.94	16.02	-
Total Liabilities	4,017	3,859	3,245	3,397	3,391	2,907
Common Stock	1,037	1,037	1,046	1,046	1,054	1,055
Additional Paid-In Capital	2,851	2,848	2,993	2,993	3,048	3,041
Retained Earnings	4,800	4,618	4,354	4,905	4,712	4,505
Treasury Stock	-	-	-159	-121.01	-186.72	-127.02
Comprehensive Income & Other	83.21	18.96	41.31	-11.36	-92.36	-34.22
Total Common Equity	8,771	8,522	8,276	8,812	8,535	8,440
Minority Interest	-114.67	-95.07	-20.73	334.75	239.38	290.36
Shareholders' Equity	8,657	8,427	8,255	9,147	8,775	8,730
Total Liabilities & Equity	12,674	12,286	11,500	12,544	12,165	11,637
Total Debt	2,296	2,294	1,995	2,177	2,274	1,660
Net Cash (Debt)	-1,510	-1,405	-1,222	-937.51	-937.76	-289.32
Net Cash Per Share	-1.25	-1.16	-1.00	-0.74	-0.77	-0.24
Filing Date Shares Outstanding	1,213	1,216	1,216	1,219	1,207	1,148
Total Common Shares Outstanding	1,213	1,216	1,216	1,219	1,207	1,148
Working Capital	935.03	791.21	1,064	1,491	1,284	1,377
Book Value Per Share	7.23	7.01	6.80	7.23	7.07	7.35
Tangible Book Value	4,276	3,958	3,855	5,323	5,139	4,975
Tangible Book Value Per Share	3.53	3.25	3.17	4.37	4.26	4.33
Buildings	992.99	985.62	973.8	914.2	931.78	841.79
Machinery	1,483	1,458	1,443	1,357	1,232	1,071
Construction In Progress	1,141	807.15	313.31	175.8	257.46	415.22

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.